Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx TM )

• Published in: Vascular and endovascular surgery Vol. 55; no. 1; p. 50
• Main Authors: Nuckles, Brandon, Nadal, Luis, Berger, Andrea, Salzler, Gregory, Elmore, James R, Ryer, Evan J
• Format: Journal Article
• Language: English
• Published: United States 01.01.2021
• Subjects: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal - surgery; Blood Vessel Prosthesis Implantation - adverse effects; Cyanoacrylates - administration & dosage; Cyanoacrylates - adverse effects; Embolization, Therapeutic - adverse effects; Embolization, Therapeutic - instrumentation; Endoleak - diagnostic imaging; Endoleak - etiology; Endoleak - therapy; Endovascular Procedures - adverse effects; Female; Humans; Male; Polyvinyls - administration & dosage; Polyvinyls - adverse effects; Retrospective Studies; Treatment Outcome; endovascular; Onyx; embolization; type 2 endoleak; abdominal aortic aneurysm; sac volume
• ISSN: 1938-9116
• DOI: 10.1177/1538574420964644

This study reports our experience with the use of an ethylene vinyl alcohol copolymer (Onyx™) for the treatment of type II endoleak after endovascular repair of abdominal aortic aneurysms (EVAR) in comparison to coils and cyanoacrylate glue. Clinical data of all patients treated for type II endoleak following EVAR between 2009 and 2017 were retrospectively analyzed. Abdominal aortic aneurysm (AAA) diameter and AAA sac volume during follow-up were measured using computed tomography angiography (CTA). Treatment failure variables were created for the change in sac diameter and volume. An increase in sac diameter ≥ 5 mm was considered a failure, as was an increase ≥ 10% in AAA sac volume. 35 patients underwent treatment for a persistent type II endoleak following EVAR. Of these patients, 18 (51.4%) were treated with Onyx and 17 (48.6%) were treated with coils ± cyanoacrylate glue embolization. There were no significant differences between the 2 groups with regard to demographics. The average volume of Onyx used per treatment was 13.4 ml (range 4.5 ml- 39 ml). There was no difference in efficacy between the Onyx and non-Onyx group. Complications were limited to 1 non-target embolization without significant clinical sequelae. Ethylene vinyl alcohol copolymer (Onyx™) embolization is similarly effective compared to traditional cyanoacrylate glue or coil embolization in the treatment of type II endoleak after EVAR.